List of Tissue Engineering Companies in United States - 49

3D Biotek, LLC is a high tech biomedical engineering company located in the state of New Jersey, USA. Using its Precision 3D Micro-fabrication Technology and Advanced Bio-manufacturing Technology, 3D Biotek is a leader and the industry's only dedicated driving force in the research and development of novel 3-dimensional cell culture devices for stem cell/tissue engineering, drug discovery and broad cell biology applications.

We are committed to the growth and development of companies and organizations using advanced therapeutic technologies to revolutionize medicine through specialized, bespoke advisory services. At Adjuvant Partners, we leverage our expertise, professional network, and pan-industry perspectives to provide unique, tailored solutions to our clients to best suit their needs. We believe in active participation with stakeholders throughout the industry, and in concert with our clientele work to foster continued growth, expansion, and implementation of advanced therapies across the healthcare spectrum.

Advanced BioMatrix provides innovative 3D matrix products, transforming science to a new level of discovery. We extract and manufacture highly purified, native, extracellular matrix proteins for tissue engineering, 3D bioprinting, cell culture, drug discovery and any other application with cells. Visit us at www.advancedbiomatrix.com or our 3D bioprinting page at www.bioprintabm.com

For more than 30 years, Advanced Solutions, a privately held company, focused on long-term investments in technology companies that deliver profound and positive engineering solutions for healthcare, manufacturing, workflow optimization, logistics and education. Companies include: Advanced Solutions Life Sciences, Power of Public Speaking, Expedient, and IDS Engineering. Advanced Solutions Design Software and Advanced Solutions PLM are now part of IMAGINiT Technologies

Allevi Develops 3D printers fof bioinks. Bioinks are materials that mimic an extracellular matrix environment to support the adhesion, proliferation, and differentiation of living cells. From GelMA to Collagen and from Hyperelastic Bone to Graphene, Allevi offers the widest range of material capabilities.

Atreon Orthopedics is a tissue regeneration company powered by breakthrough regenerative technology and renowned scientific expertise. Tendon and ligament injuries affect ten million people yearly, spanning all lifestyles and demographics. Atreon is committed to dramatically improving healing and long-term outcomes for patients encountering these soft-tissue injuries. ROTIUM®, our initial product for rotator cuff repair, is a bioresorbable wick designed as a scaffold to harness and hold biologically active substances at the repair site providing a pro-healing environment that promotes healthy tissue and native tissue regeneration. Recently published human and animal studies and over 10,000 cases have shown a safe and effective solution to improving biology, restoring function, and improving rotator cuff success rates.

Avery Therapeutics is developing first-in-class immunomodulatory therapeutics to redirect the immune system to address diseases of aging, inflammation, and fibrosis. Avery's lead program is under development for heart failure, one of the leading causes of death in the world.

Axonova Medical is pursuing a disruptive technology that can effectively recreate lost or damaged neural circuitry following neurological injuries. They are a developer of tissue engineered nerve grafts for nerve repair.

AxoSim empowers advancements in human neuroscience by partnering with biopharma companies to facilitate breakthroughs in devastating neurological diseases and disorders. Their proprietary drug discovery platforms NerveSim®, BrainSim®, and microBrain™ deliver clinically-relevant data to select better lead candidates with phenotypically accurate assays. AxoSim's platforms have applications in peripheral neuropathy and neuropathic pain, disease modeling (such as ALS, MS, and CMT), and neurotoxicology.

An innovation driven start up company catering to the unmet needs of the biomaterial community and medical device industry. With our state of the art research and development facilities in theUS and India, combined with our platform technologies derived from a family of novel and proprietary biodegradable polymeric biomaterials, we work with and for our customers to translate their demands into high quality products for a wide range of medical device and therapeutic applications in a cost effective manner. Our expertise lies in the area of absorbable polyurethanes, absorbable polymers derived from functionalized natural products, drug molecules and amino acids, adhesion prevention barriers, absorbable drug eluting stent coatings, tissue adhesive and sealant, medical device coatings, drug delivery, drug device combination, absorbable implantable devices and tissue engineering.

Pioneered by accomplished business leaders, guided by world-class biomedical and life science experts, and financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death worldwide. Leveraging advances in life sciences and cardiac tissue engineering to build human hearts suitable for implantation, this biotech company is committed to optimizing the process and technology around viable human organ replacement, and making it a safe, accessible, commercially viable, and cost-effective reality.

Our unique modular closure system is called the Xvivo System model X2. Many people dismiss it as simply another isolator. It does look like one and has glove access where necessary in the workflow. However, unlike isolators it has extensive plug-and-play modularity so it can enclose any production process. Less obvious but just as important, it can easily be reconfigured to quickly accommodate any changes or improvements to the process such as new equipment or automation, or as you need to scale

BioTissue is the leader in innovative applications of human birth tissues for regenerative wound healing, aiming to improve patient outcomes. The company is committed to promoting regenerative healing through its birth tissue products.

CD Bioparticles is an established drug delivery company which provides customized solutions for developing and producing new, biocompatible drug delivery systems.

Cerapedics is a global, commercial-stage orthopedics company that aspires to redefine the standard of care for bone repair by healing bones faster and at higher rates, without compromising safety, so that patients can live their healthiest lives. Bone grafts, including Cerapedics’ products, are used in over four million annual spine, orthopedics, trauma and interventional procedures world-wide. Cerapedics’ product, i-FACTOR®, is FDA approved for single-level cervical spinal fusions in the United States. Cerapedics’ next-generation product is currently being evaluated for use in lumbar interbody fusion through ASPIRE, a pivotal IDE study, and has been granted a Breakthrough Device Designation by the FDA. Cerapedics is headquartered in Westminster, CO.

The Cornea Biosciences biosynthetic replacement corneal will help reduce world corneal blindness. More than 15 years of research have gone into development of the Company's cornea. It will provide a safe, affordable, biocompatible cornea for the millions of people unable to obtain corneal transplants due to a severe shortage of human corneas.

Desktop Health develops, manufactures, and markets a suite of leading 3D printing and biofabrication solutions. One of products that the company is investigating are 3D printed eardrums.

DiscGenics is a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics is harnessing the restorative potential of cells native to the intervertebral disc to develop what we hope will be a profound therapeutic option for millions of patients suffering from the debilitating effects of back pain. DiscGenics’ first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy for the treatment of patients with mild to moderate degenerative disc disease.

In many medical settings, devices are commonly used to help doctors treat patients. For example, stents are often used to open blocked arteries, repair torn vessels, and even to keep nasal passages from swelling shut after surgery. Unfortunately these devices fail often resulting in additional surgeries and often replacements of the original device. Endomimetics has developed a BioNanomatrix that can be used to coat these devices and mimic human tissue which minimizes the need for additional surgeries, improves the longevity of the device, reduces complications associated with having foreign items implanted in your body. Applications Our endothelium mimicking nitric oxide releasing BioNanomatrix, initially developed for coronary and peripheral stents, is being assessed for several novel applications including: Stents to help with heart disease Stents and blood flow diverters to help with brain aneurysms Fistula implantation for dialysis patients Intranasal implants for chronic sinusitis sufferers

EpiBone is a revolutionary bone reconstruction company that allows patients to "grow their own bone". EpiBone's pioneering technology utilizes a scan of the patient's bone defect and the patient's own stem cells to construct and cultivate a defect-specific autologous-like bone graft. EpiBone is strategically positioned to provide a superior bone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times, without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year.

Frontier Bio creates engineered tissues to replace animal testing and save lives.

Gel4Med is a Smart Materials Company focused on regenerative medicine, with a particular emphasis on developing therapeutic materials to address unmet clinical needs. They have received FDA clearance for their products and are collaborating with organizations like The Miami Project to study novel treatments for spinal cord injuries.

Discover the limitless potential of human induced pluripotent stem cells (iPSCs) for groundbreaking research at Greenstone, a leading Bay Area biotech company. We combine cutting-edge technology with AI, computational biology, and pharmacogenomics to accelerate drug discovery and development, transforming the future of therapeutics. Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform. By harnessing the power of iPSCs and our advanced technologies, we revolutionize the traditional drug discovery paradigm, paving the way for a faster, more efficient approach. With our curated and diverse collection of iPSCs, sourced from both healthy individuals and those affected by various diseases, we offer a comprehensive platform for disease modeling, uncovering novel mechanisms, and advancing drug discovery. Our high-quality iPSCs provide researchers with patient-specific and disease-specific cells, enabling the development of personalized treatment strategies. At Greenstone, collaboration and innovation are at the core of our values. We proudly offer our iPSCs to academic investigators free of cost, fostering an environment of shared knowledge and progress. Together, we can unlock new insights, accelerate drug discovery, and shape the future of personalized medicine. Join us on the frontier of biomedical research and tap into the immense potential of iPSCs. Together, let's transform drug discovery into a rapid, integrated, and computational platform that propels us towards groundbreaking therapeutics. #Biotech #iPSCs #DrugDiscovery #BiomedicalResearch #PersonalizedMedicine #Innovation

HRGN is a clinical-stage biotechnology company that uses a patient’s own stem cells that are grown on a hollow tubular scaffold to regenerate organ tissue damaged from cancer, trauma, birth defects or other diseases.

Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.

Imagine Pharma is a biotechnology company focused on three distinctive platforms: oral delivery, regenerative and therapeutics. Each platform has first-in-class programs that address multiple disease states in large underserved markets.

Innervace is a regenerative therapy company developing technology that acts as pre-formed, anatomically-inspired, implantable tissue pathways to directly replace lost connections due to brain degeneration or injury. Our lead program mimics the lost migrostriatal pathway in patients with Parkinson's disease (PD).

MatTek Life Sciences is at the forefront of tissue engineering and is a world leader in the production of innovative 3D reconstructed human tissue models. Our skin, ocular, and respiratory tissue models are used in regulatory toxicology (OECD, EU guidelines) and address toxicology and efficacy concerns throughout the cosmetics, chemical, pharmaceutical and household product industries. With facilities in the U.S. and Slovakia, MatTek's human cell-derived tissue models are widely used in the United States, Europe and Japan. Our record of scientific and technological innovation remains strong as we continue to develop and validate new in vitro assays, human tissue models and optically advanced cultureware. We invite you to use our products, services and technical solutions, which will afford your company new opportunities in obtaining faster, cost-effective, more reliable and human-relevant results compared to the traditional assays and 2D in vitro systems.

MLM Biologics Inc. (MLM) is a Delaware C-Corp company founded on the modern interpretation of Gandhian Economic Principle of "More for Less for Many". The company utilizes their expertise in chemistry and biology of scaffolds, and a proprietary processing platform, to deliver evidence-based solutions for musculoskeletal and wound care problems.

NovoThelium is a San Antonio based biotechnology company developing a tissue-engineered matrix for nipple regeneration after mastectomy.

We are pioneering a unique set of therapeutic and drug profiling capabilities based on our revolutionary ability to 3D bioprint tissues that mimic key aspects of human biology and disease. We intend to fundamentally alter the drug discovery landscape by the development of novel therapies for disease which have a much higher chance of efficacy in the clinic focused on human primary cell 3D models of disease that more faithfully recapitulate disease processes. Learn more at www.organovo.com.

Discover Phycin's pioneering solution for ocular injuries – a groundbreaking therapy derived from the miraculous world of algae! As a leading innovator in growth factor technology, we present an unparalleled approach to transform the treatment of corneal damage for both military personnel and the general public.

PolyOrg, Inc., founded in 2003, provides comprehensive chemical synthesis services to life science companies and research universities. We help our customers develop new products, improve existing products, and transition their existing products from research to manufacturing. We perform contract research, process development, custom synthesis, and manufacturing for clients in various science industries. Our clients are primarily in the pharmaceutical, biotechnology, specialty chemicals, and diagnostic industries. We employ expert Ph.D. chemists and process technicians skilled in organic, solid phase, medicinal, natural product, and polymer chemistry. For inquiries or quotation requests, email info@polyorginc.com.

Ponte Biosciences, Inc. is a preclinical biotherapeutic company focused on developing a cell-based bioartificial liver system to treat acute forms of liver failure. The Company's Spheroid Reservoir Bioartificial Liver (SRBAL) system was developed at the Mayo Clinic and utilizes metabolically active primary hepatocytes (liver cells) to replace and/or supplement liver function for patients with liver failure being treated in the Intensive Care Unit (ICU).

Precise Bio develops and commercializes 4D bio-fabricated functional tissues and organs that can save lives and improve its quality. We combine world-class tissue-engineering and transplantation experience with best-in-class bio-printing, to create a scalable bio-fabrication platform, that can overcome current industry challenges and make complex human organs available for transplantation.

Prellis Bio is hiring Immunologists! We are expanding our Externalized Immune System, EXIS™, platform with applications in antibody discovery, immunogenicity, and vaccine screening all in the same platform. Prellis Biologics, Inc. is a privately held company based in the San Francisco Bay Area, CA. Apply at www.prellisbio.com.

RegenLab is recognized as a global leader in medical biotechnologies, specializing in cellular therapies, manufactured in the USA. RegenLab is at the forefront of innovation, with an expertly designed medical device for the preparation of platelet rich plasma from the patient's own blood. Regen® A-PRP® is FDA cleared and developed with a focus on product quality, patient safety, and preparation efficiency. Our patient-centered technology has led to over one million treatments worldwide using RegenLab products. As we look to the future, we are committed to guiding new standards for emerging categories within the field of regenerative medicine.

RTI Surgical (RTI) is a leading CDMO pushing the boundaries of innovation and tissue engineering to meet patient needs in regenerative medicine. We are expert partners to Original Equipment Manufacturers (OEMs), working with them to identify clinical problems and develop customized solutions that promote healing, accelerate recovery, and help prevent complications. We focus on specialized clinical segments, including breast and plastic surgery, sports medicine and orthopedics, and neuro and spine surgery. Our Mission is to enhance patients' lives by creating the best clinical outcomes through innovative, high-quality medical solutions.

SpineSmith designs, develops and markets implants and biologics for surgical fixation, correction and tissue regeneration of the spine. We take a different approach from other companies, utilizing a collaborative process between engineers and spine surgeons. This approach results in the development of truly innovative biological and hardware technologies for use in the treatment of patients with spinal disorders. Our unique, think-tank philosophy gives spine surgeons the ability to directly impact the direction of our product portfolio, ensuring applicability and the highest possible standards of quality.

Tempo Therapeutics is a biotechnology company that specializes in tissue engineering using proprietary MAP material science technology to build functional tissue and organs within patients in real time for disease treatment.

Tolerance Bio will increase health span by preserving and restoring the function of the thymus, the master regulator of immune tolerance. Immune-mediated diseases represent a significant unmet medical challenge: cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergies.

Trestle Biotherapeutics, Inc. is a preclinical stage company developing bioengineered therapies for patients living with end stage renal disease. Once implanted, these bioengineered stem cell-derived tissues will get patients off dialysis, delay their need for transplantation, and one day become replacement organs.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. We currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! Our employees can be found collaborating across the United States, Europe and Asia. As a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases.

Vascugen is dedicated to revolutionizing the standard of care for millions of patients suffering from severe conditions caused by restricted blood flow, particularly for those patients at high risk for amputation and death for whom few to no treatment options remain. The company’s lead product is an allogeneic vasculogenic cell – a cell with the potential to forge new blood vessels in oxygen-starved tissues. The vasculogenic cell product is manufactured from induced pluripotent stem cells (iPSCs), which provide a limitless source from which to produce off-the-shelf, cryopreserved doses at scale.

VenoStent is a tissue engineering medical device company developing bioabsorbable polymer wraps for better outcomes in vascular surgery.

Vitanova Biomedical is a San Antonio, Texas-based early stage biotechnology company focused on delivering transformative cancer therapy utilizing Light-Activated Intracellular Acidosis.

The Wake Forest Institute for Regenerative Medicine is working to grow tissues and organs and develop healing cell therapies for more than 30 different areas of the body, from kidney and trachea to cartilage and lung.

At the Wyss Institute, we leverage recent insights into how Nature builds, controls and manufactures to develop new engineering innovations - a new field of research we call Biologically Inspired Engineering. Our scientists, engineers and clinicians, who come from Harvard's Schools of Medicine, Engineering, Arts & Sciences, Design, and Education as well as 12 collaborating academic institutions and hospitals, work alongside staff with industrial experience in product development to engineer transformative solutions to some of the world’s greatest problems. By emulating biological principles of self assembly, organization and regulation, we are developing disruptive technology solutions for healthcare, energy, architecture, robotics, and manufacturing, which are translated into commercial products and therapies through formation of new startups and corporate alliances.